Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: HIV vaccines - Immunotech Laboratories

Next Previous
Drug Profile

Research programme: HIV vaccines - Immunotech Laboratories

Alternative Names: Immune therapeutic vaccine-2; Immune therapeutic vaccine-3; Immune therapeutic vaccine-4; Inactivated pepsin fraction HIV vaccine - Immunotech Laboratories; IPF-ITV; IPF-ITV-2; IPF-ITV-3; Irreversible pepsin fraction HIV vaccine - Immunotech Laboratories; ITV-2; ITV-3; ITV-4

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Immunotech Laboratories
  • Class AIDS vaccines; Peptide vaccines
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections(In children) in USA (Parenteral)
  • 26 Apr 2013 Immunotech files an IND application with the FDA in US for HIV infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top